<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isatuximab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isatuximab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isatuximab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="127395" href="/d/html/127395.html" rel="external">see "Isatuximab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54179800"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sarclisa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54736261"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Sarclisa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54174937"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD38;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54231894"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Premedications are required prior to infusion to reduce the risk and severity of infusion reactions. Administer in a facility with immediate access to emergency equipment and support to manage infusion reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing is based on actual body weight (measure weight and adjust dose at the beginning of each cycle).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Initiate antiviral prophylaxis to prevent herpes zoster reactivation according to clinical and institutional guidelines. Consider antibacterial prophylaxis during isatuximab treatment. Conduct blood type and screening prior to the first isatuximab infusion; consider phenotyping prior to initiating treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac522d92-c8b2-419c-959b-57ffc7ab0312">Multiple myeloma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Cycle 1: <b>IV: </b>10 mg/kg on days 1, 8, 15, and 22 of a 28-day cycle (in combination with pomalidomide and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735560'])">Ref</a></span>) <b>or</b> in combination with carfilzomib and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37156782','lexi-content-ref-34097854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37156782','lexi-content-ref-34097854'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:4em;">Cycle 2 and beyond: <b>IV: </b>10 mg/kg on days 1 and 15 of a 28-day cycle (in combination with pomalidomide and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735560'])">Ref</a></span>) <b>or </b>in combination with carfilzomib and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37156782','lexi-content-ref-34097854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37156782','lexi-content-ref-34097854'])">Ref</a></span>)), continue until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a planned isatuximab dose is missed, administer the dose as soon as possible and then adjust the treatment schedule accordingly, maintaining the treatment interval.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedications:</b> Administer 15 to 60 minutes prior to initiating isatuximab infusion to reduce the risk and severity of infusion reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">- Dexamethasone: Dose corresponds to the dose used as part of the backbone combination treatment; administer only once on days isatuximab is administered.</p>
<p style="text-indent:-2em;margin-left:6em;">Isatuximab, pomalidomide, and dexamethasone regimen: 40 mg IV or oral (20 mg IV or oral in patients ≥75 years of age).</p>
<p style="text-indent:-2em;margin-left:6em;">Isatuximab, carfilzomib, and dexamethasone regimen: 20 mg IV on the days isatuximab and/or carfilzomib are administered. Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">- Acetaminophen 650 mg to 1 g oral (or equivalent).</p>
<p style="text-indent:-2em;margin-left:4em;">- An H<sub>2</sub> antagonist.</p>
<p style="text-indent:-2em;margin-left:4em;">- Diphenhydramine 25 to 50 mg IV or oral (or equivalent); for at least the first 4 infusions, the IV route is preferred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54231896"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary.</p></div>
<div class="block doha drugH1Div" id="F54231897"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">No dosage adjustment is necessary.</p></div>
<div class="block doo drugH1Div" id="F57498255"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F54231898"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> No isatuximab dose reduction is recommended. Other concomitant anticancer therapies may also require dosage modification.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Isatuximab Recommended Dosage Adjustments for Adverse Reactions</b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="left">
<p style="text-indent:0em;">Severity</p></th>
<th align="left">
<p style="text-indent:0em;">Isatuximab dosage modification</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">Hematologic toxicity</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;">Delay isatuximab until neutrophil count recovers to ≥1,000/mm<sup>3</sup> and provide supportive care with growth factors (according to institutional guidelines).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">Nonhematologic toxicity</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Infusion reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2 or 3 reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt isatuximab infusion and provide appropriate medical management.</p>
<p style="text-indent:0em;">
<i>Symptoms improve to grade 1 or lower after infusion interruption</i>: Restart isatuximab infusion at half of the initial infusion rate with close monitoring (and with supportive care as needed); if symptoms do not recur after 30 minutes, may increase the infusion rate to the initial rate, and then increase incrementally.</p>
<p style="text-indent:0em;">
<i>Symptoms do <b>not</b> improve to grade 1 or lower after infusion interruption, persist or worsen despite medical management, or hospitalization required</i>: Permanently discontinue isatuximab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4 (life-threatening) or anaphylactic reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue isatuximab (and provide appropriate medical management).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Second primary malignancy (skin cancers)</p></td>
<td align="left">
<p style="text-indent:0em;">Any</p></td>
<td align="left">
<p style="text-indent:0em;">Patients with non-melanoma skin cancer were able to continue isatuximab treatment after resection of the skin cancer.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54231895"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54326367"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isatuximab (in combination with carfilzomib or pomalidomide and dexamethasone) commonly causes <b>neutropenia</b> (including grades 3 and 4 neutropenia), <b>febrile neutropenia</b>, and <b>neutropenic infection</b>. The most frequently occurring neutropenic infections during clinical trials included <b>upper respiratory tract infections</b>, <b>pneumonia, </b>and urinary tract infections. In one trial, median duration of grade ≥3 neutropenia was 9 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30862646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30862646'])">Ref</a></span>). May require treatment interruption. <b>Anemia</b>, <b>lymphocytopenia</b>, and <b>thrombocytopenia</b> have also commonly been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926770'])">Ref</a></span>); impact of concurrent drugs must be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; in one trial, median time to onset of first grade ≥3 neutropenia was 22 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30862646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30862646'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions</b> are commonly observed with isatuximab (in combination with carfilzomib or pomalidomide and dexamethasone); most often characterized by <b>cough</b>, <b>dyspnea</b>, <b>nasal congestion</b>, and <b>nausea</b>. Patients who develop severe symptoms often experience <b>bronchospasm</b>, <b>dyspnea</b>, and <b>hypertension</b>. <b>Angioedema</b>, <b>swelling, </b>and <b>hypotension</b> may also occur; <b>anaphylaxis</b> has been reported rarely. During clinical trials, most infusion reactions resolved on the same day either spontaneously or with treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735560','lexi-content-ref-30862646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735560','lexi-content-ref-30862646'])">Ref</a></span>). Infusion reactions may result in treatment interruption, infusion rate adjustment, or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30926770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30926770'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; most reactions occurred during the first infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31735560','lexi-content-ref-30862646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31735560','lexi-content-ref-30862646'])">Ref</a></span>). The median time to infusion interruption due to infusion-related reactions was 55 minutes in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Faster rate of infusion</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Second primary malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Second primary malignant neoplasms</b> (SPM) have been reported with isatuximab (in combination with carfilzomib or pomalidomide and dexamethasone) and include <b>malignant neoplasm of the skin </b>and<b> malignant solid tumor</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i> Time-related. Exact mechanism is not established; impact of disease process and concurrent medications must be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; in clinical trials, the median interval from first dose to diagnosis of SPM was ~7 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-BLA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-BLA.2019'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54247595"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in combination with carfilzomib or pomalidomide plus dexamethasone.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (37%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypertension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carfilzomib + Dexamethasone) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (26% to 36%; grade 3: 2% to 3%), nausea (15%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (12% to 15%; grade 3: 1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pomalidomide + Dexamethasone) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (99%; grade 3: 22% to 32%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 3</a>)</span><span class="table-link" style="display:none;">Anemia</span>, febrile neutropenia (1% to 12%; grade 3: 11%; grade 4: 1%)<span class="lexi-table-link-container"> (<a aria-label="Febrile Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-febrile-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-febrile-neutropenia')">table 4</a>)</span><span class="table-link" style="display:none;">Febrile Neutropenia</span>, lymphocytopenia (92% to 94%; grade 3: 42% to 52%; grade 4: 13% to 17%<span class="lexi-table-link-container"> (<a aria-label="Lymphocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-lymphocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-lymphocytopenia')">table 5</a>)</span><span class="table-link" style="display:none;">Lymphocytopenia</span>), neutropenia (55% to 96%; grade 3: 18% to 24%; grade 4: 2% to 61%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 6</a>)</span><span class="table-link" style="display:none;">Neutropenia</span>, thrombocytopenia (84% to 94%; grade 3: 14% to 19%; grade 4: 11% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-thrombocytopenia')">table 7</a>)</span><span class="table-link" style="display:none;">Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 99%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 99%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Febrile Neutropenia" frame="border" id="lexi-content-febrile-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Febrile Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pomalidomide + Dexamethasone) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Lymphocytopenia" frame="border" id="lexi-content-lymphocytopenia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Lymphocytopenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 94%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 92%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">92%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 52%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 96%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">92%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 61%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 55%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Thrombocytopenia" frame="border" id="lexi-content-thrombocytopenia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 94%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">88%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 84%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4: 11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (38% to 46%; including severe infusion-related reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (grades 3/4: 38% to 43%), neutropenic infection (2% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (24%), cough (23%<span class="lexi-table-link-container"> (<a aria-label="Cough table link" class="lexi-table-link" data-table-id="lexi-content-cough" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cough')">table 8</a>)</span><span class="table-link" style="display:none;">Cough</span>), dyspnea (17% to 29%)<span class="lexi-table-link-container"> (<a aria-label="Dyspnea table link" class="lexi-table-link" data-table-id="lexi-content-dyspnea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspnea')">table 9</a>)</span><span class="table-link" style="display:none;">Dyspnea</span>, pneumonia (31% to 36%)<span class="lexi-table-link-container"> (<a aria-label="Pneumonia table link" class="lexi-table-link" data-table-id="lexi-content-pneumonia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pneumonia')">table 10</a>)</span><span class="table-link" style="display:none;">Pneumonia</span>, upper respiratory tract infection (57% to 67%)<span class="lexi-table-link-container"> (<a aria-label="Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-upper-respiratory-tract-infection')">table 11</a>)</span><span class="table-link" style="display:none;">Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cough" frame="border" id="lexi-content-cough" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Cough</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carfilzomib + Dexamethasone) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspnea" frame="border" id="lexi-content-dyspnea" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Dyspnea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pneumonia" frame="border" id="lexi-content-pneumonia" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Pneumonia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Upper Respiratory Tract Infection" frame="border" id="lexi-content-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pomalidomide + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carfilzomib + Dexamethasone) </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isatuximab + Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator) </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">67%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular<b>: </b>Heart failure (serious: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Malignant neoplasm of skin (4%)<span class="lexi-table-link-container"> (<a aria-label="Malignant Neoplasm of Skin table link" class="lexi-table-link" data-table-id="lexi-content-malignant-neoplasm-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-malignant-neoplasm-of-skin')">table 12</a>)</span><span class="table-link" style="display:none;">Malignant Neoplasm of Skin</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Malignant Neoplasm of Skin" frame="border" id="lexi-content-malignant-neoplasm-of-skin" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Malignant Neoplasm of Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab+ Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant solid tumor (2%)<span class="lexi-table-link-container"> (<a aria-label="Malignant Solid Tumor table link" class="lexi-table-link" data-table-id="lexi-content-malignant-solid-tumor" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-malignant-solid-tumor')">table 13</a>)</span><span class="table-link" style="display:none;">Malignant Solid Tumor</span>, second primary malignant neoplasm (4% to 7%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Malignant Solid Tumor" frame="border" id="lexi-content-malignant-solid-tumor" rules="all">
<caption style="text-align:center;">
<b>Isatuximab: Adverse Reaction: Malignant Solid Tumor</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isatuximab+ Pomalidomide or Carfilzomib + Dexamethasone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, cytokine release syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Swelling</p></div>
<div class="block coi drugH1Div" id="F54172831"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to isatuximab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54231691"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F54179801"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sarclisa: isatuximab-irfc 20 mg/mL (5 mL, 25 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F54179799"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54266797"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sarclisa Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $185.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/25 mL (per mL): $185.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54736262"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sarclisa: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F54308150"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Available through authorized specialty distributors and specialty pharmacies. Information regarding distribution is available from the manufacturer at SanofiCareAssist.com/hcp/Sarclisa or at 1-833-930-2273.</p></div>
<div class="block adm drugH1Div" id="F54231899"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer as an IV infusion using an IV tubing infusion set made of polyethylene, polyvinyl chloride (PVC) with or without di-2-ethylhexyl phthalate (DEHP), polybutadiene, or polyurethane with a 0.22 micron in-line polyethersulfone, polysulfone, or nylon filter. Infusion duration depends on the rate of infusion. Do not infuse with other medications via the same IV line.</p>
<p style="text-indent:-2em;margin-left:2em;">When used in combination with carfilzomib and dexamethasone, on the days when both isatuximab and carfilzomib are administered, administer dexamethasone first, followed by isatuximab, and then carfilzomib.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion rate (based on a 250 mL infusion bag volume; escalate infusion rate only in the absence of infusion reactions):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>First infusion:</i> Initiate at 25 mL/hour for 60 minutes; if tolerated, increase rate by 25 mL/hour every 30 minutes to a maximum rate of 150 mL/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Second infusion:</i> Initiate at 50 mL/hour for 30 minutes; if tolerated, increase rate by 50 mL/hour for 30 minutes, then increase rate by 100 mL/hour to a maximum rate of 200 mL/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Subsequent infusions:</i> Initiate at 200 mL/hour; maximum rate: 200 mL/hour.</p></div>
<div class="block use drugH1Div" id="F54172830"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of multiple myeloma (in combination with pomalidomide and dexamethasone) in adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (in combination with carfilzomib and dexamethasone) in adults who have received 1 to 3 prior lines of therapy.</p></div>
<div class="block mst drugH1Div" id="F54231685"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isatuximab may be confused with daratumumab, dinutuximab, elotuzumab, ipilimumab, ixabepilone, ixazomib, loncastuximab tesirine, margetuximab, siltuximab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54254487"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54254484"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54231689"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 5 months after the last isatuximab dose.</p>
<p style="text-indent:0em;margin-top:2em;">Isatuximab is used in combination with pomalidomide; also refer to the Pomalidomide monograph for additional information related to use in patients who could become pregnant and patients with partners who could become pregnant.</p></div>
<div class="block pri drugH1Div" id="F54231688"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Isatuximab is a monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, in utero exposure to isatuximab may cause fetal harm, including depletion of fetal CD38-positive immune cells and decreased bone density.</p>
<p style="text-indent:0em;margin-top:2em;">Isatuximab is used in combination with pomalidomide; pomalidomide is contraindicated for use during pregnancy. Refer to the pomalidomide monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F54231690"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if isatuximab is present in breast milk. However, isatuximab is a monoclonal antibody (IgG<sub>1</sub>) and maternal IgG is known to be present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. Isatuximab is used in combination with pomalidomide; refer to the pomalidomide monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F54231902"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Conduct blood type and screening prior to the first isatuximab infusion; consider phenotyping prior to starting isatuximab treatment. Monitor CBC periodically during treatment. Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor vital signs frequently during entire infusion; monitor for signs/symptoms of infusion reaction. Monitor patients with neutropenia for signs of infection; monitor for the development of second primary malignancies.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54231890"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Isatuximab is an IgG1-derived monoclonal antibody directed against CD38. CD38 is expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab has antitumor activity via antibody-dependent, cell-mediated cytotoxicity; complement-dependent cytotoxicity; and antibody-dependent cellular phagocytosis and directly inhibits activity of CD38 ectoenzymes (Attal 2019). Isatuximab can activate natural killer cells in the absence of CD38-positive target tumor cells and suppresses CD38-positive T-regulatory cells. The combination of isatuximab plus pomalidomide enhanced antibody-dependent, cell-mediated cytotoxicity activity and direct tumor cell killing compared to isatuximab alone (in vitro) and enhanced antitumor activity compared to isatuximab or pomalidomide activities alone in animal models.</p></div>
<div class="block phk drugH1Div" id="F54231891"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.13 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides by catabolic pathways.</p></div>
<div class="block phksp drugH1Div" id="F55733363"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Isatuximab clearance increases with increasing body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522042"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sarclisa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31735560">
<a name="31735560"></a>Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in <i>Lancet</i>. 2019;394(10214):2072]. <i>Lancet</i>. 2019;394(10214):2096-2107. doi:10.1016/S0140-6736(19)32556-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/31735560/pubmed" id="31735560" target="_blank">31735560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi: 10.1034/j.1600-0536.2002.4705104.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37156782">
<a name="37156782"></a>Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. <i>Blood Cancer J</i>. 2023;13(1):72. doi:10.1038/s41408-023-00797-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/37156782/pubmed" id="37156782" target="_blank">37156782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926770">
<a name="30926770"></a>Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. <i>Blood Cancer J</i>. 2019;9(4):41. doi:10.1038/s41408-019-0198-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/30926770/pubmed" id="30926770" target="_blank">30926770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30862646">
<a name="30862646"></a>Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i>. 2019;134(2):123–133. doi:10.1182/blood-2019-02-895193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/30862646/pubmed" id="30862646" target="_blank">30862646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34097854">
<a name="34097854"></a>Moreau P, Dimopoulos MA, Mikhael J, et al; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i>. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/34097854/pubmed" id="34097854" target="_blank">34097854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BLA.2019">
<a name="BLA.2019"></a>Sarclisa (isatuximab) biologics license application (BLA) multi-disciplinary review and evaluation. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761113Orig1s000MultidisciplineR.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761113Orig1s000MultidisciplineR.pdf</a>. Published April 30, 2019. Accessed November 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.1">
<a name="Sanofi.1"></a>Sarclisa (isatuximab) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isatuximab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127258 Version 109.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
